MYLK2

Across TCGA pan-cancer cohorts, MYLK2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MYLK2 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MYLK2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYLK2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC and HNSC are the cancer types where MYLK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.407	0.599	.036	4	view →
HNSC	DFS	Tertile	IV	0.844	0.617	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MYLK2–PDAC (OS)

Open the PDAC breakdown →